1-5 of 5
Thomas Friess, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Clinical BET Inhibitor RG6146 Demonstrates Potent and on-Target Activity in Pre-Clinical Models of Hematological Malignancy and Combines with Anti-CD20 and BCL-2 Inhibition to Provide Superior Efficacy

Astrid Rueflibrasse, PhD, Thomas Friess, PhD, Stephanie Lechner, Lisa Wellinger, Jurriaan Brouwer, William E. Pierceall, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2071.
https://doi.org/10.1182/blood.V130.Suppl_1.2071.2071
Published: 2017
Journal Articles

The Triple Combination of the CD20 Antibody Obinutuzumab with the Bcl-2 Inhibitor Venetoclax (GDC-199) and the MDM2 Inhibitor Idasanutlin Results in Superior Efficacy and Long Term Response in Wildtype p53 NHL Tumor Models

Frank Herting, PhD, Thomas Friess, PhD, Pablo Umaña, PhD, Middleton Steven, PhD, Christian Klein, PhD
Journal: Blood
Blood (2016) 128 (22): 4178.
https://doi.org/10.1182/blood.V128.22.4178.4178
Published: 2016
Journal Articles

Combination of the Glycoengineered Type II CD20 Antibody Obinutuzumab (GA101) and the MDM2 Selective Antagonist RG7388 Results in Superior Anti-Tumor Activity

Frank Herting, PhD, Sylvia Herter, PhD, Thomas Friess, PhD, Christian Lehmann, PhD, Marina Bacac, PhD, Markus Dangl, PhD, Christian Klein, PhD
Journal: Blood
Blood (2014) 124 (21): 1780.
https://doi.org/10.1182/blood.V124.21.1780.1780
Published: 2014
Journal Articles

GA101, a Novel Humanized Type II CD20 Antibody with Glycoengineered Fc and Enhanced Cell Death Induction, Mediates Superior Efficacy in a Variety of NHL Xenograft Models in Comparison to Rituximab.

Thomas Friess, PhD, Christian Gerdes, PhD, Adam Nopora, PhD, Monika Patre, PhD, Susanne Preiss, PhD, Erwin van Puijenbroek, Christine Schuell, PhD, Sabine Bauer, PhD, Pablo Umana, PhD, Christian Klein, PhD
Journal: Blood
Blood (2007) 110 (11): 2338.
https://doi.org/10.1182/blood.V110.11.2338.2338
Published: 2007
Journal Articles

GA101, a Novel Humanized Type II CD20 Antibody with Glycoengineered Fc and Enhanced Cell Death Induction, Exhibits Superior Anti-Tumor Efficacy and Superior Tissue B Cell Depletion In Vivo.

Pablo Umana, PhD, Moessner Ekkehard, PhD, Bruenker Peter, PhD, Klingner Gabriele, Puentener Ursula, PhD, Tobias Suter, PhD, Roger Grau, PhD, Carla Schmidt, PhD, Sylvia Herter, PhD, Christian Gerdes, PhD, Adam Nopora, PhD, Monika Patre, PhD, Samuel Moser, PhD, Peter Sondermann, PhD, Luise Wheat, PhD, Martin J.S. Dyer, PhD, Sibrand Poppema, PhD, Sabine Bauer, PhD, Manfred Kubbies, PhD, Pamela Strein, PhD, Georg Fertig, PhD, Thomas Friess, PhD, Karim Dabbagh, PhD, Joe DalPorto, PhD, Christian Klein, PhD
Journal: Blood
Blood (2007) 110 (11): 2348.
https://doi.org/10.1182/blood.V110.11.2348.2348
Published: 2007